Carregant...
Current Alzheimer's disease clinical trials: Methods and placebo outcomes
BACKGROUND: Eighteen-month-long randomized, placebo-controlled clinical trials are common for phase II and phase III drug development for Alzheimer's disease (AD). Yet, no 18-month trial has shown statistically significant outcomes favoring the test drug. We examined characteristics and underly...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3321732/ https://ncbi.nlm.nih.gov/pubmed/19751918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2009.07.038 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|